Search Results - "Scarfò, L."

Recurrent mutations refine prognosis in chronic lymphocytic leukemia by Baliakas, P, Hadzidimitriou, A, Sutton, L-A, Rossi, D, Minga, E, Villamor, N, Larrayoz, M, Kminkova, J, Agathangelidis, A, Davis, Z, Tausch, E, Stalika, E, Kantorova, B, Mansouri, L, Scarfò, L, Cortese, D, Navrkalova, V, Rose-Zerilli, M J J, Smedby, K E, Juliusson, G, Anagnostopoulos, A, Makris, A M, Navarro, A, Delgado, J, Oscier, D, Belessi, C, Stilgenbauer, S, Ghia, P, Pospisilova, S, Gaidano, G, Campo, E, Strefford, J C, Stamatopoulos, K, Rosenquist, R

“…Through the European Research Initiative on chronic lymphocytic leukemia (CLL) (ERIC), we screened 3490 patients with CLL for mutations within the NOTCH1 ( n…”
Get full text

High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial by Ferreri, A.J.M., Sassone, M., Kiesewetter, B., Govi, S., Scarfò, L., Donadoni, G., Raderer, M.

“…Clarithromycin displays immunomodulatory and antineoplastic properties. As single agent, this macrolide is associated with tumor responses in anecdotal cases…”
Get full text

Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL by Campanella, A., Capasso, A., Heltai, S., Taccetti, C., Albi, E., Herishanu, Y., Haggenburg, S., Chatzikonstantinou, T., Doubek, M., Kättström, M., Giannopoulos, K., Simkovic, M., Moreno, C., Massaia, M., Bumbea, H., Alshemmari, S., Ranghetti, P., Perotta, E., Martini, F., Sant'Antonio, E., Colia, M., Combi, C., Levi, S., Kater, A. P., Hazenberg, M., Nijhof, I. S., Hofsink, Q., Demosthenous, C., Kotaskova, J., Zaleska, J., Vrbacky, F., Raya, A. Mora, Bisogno, D., Tripoli, I. E., Popov, V. M., Roman, V., Stavroyianni, N., Karypidou, M., Scarano, E., Locatelli, M., Frenquelli, M., Scarfò, L., Stamatopoulos, K., Ghia, P.

“…Profound immune dysregulation and impaired response to the SARS‐CoV‐2 vaccine put patients with chronic lymphocytic leukemia (CLL) at risk of severe COVID‐19…”
Get full text

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0 by Kiesewetter, B., Dafni, U., de Vries, E.G.E., Barriuso, J., Curigliano, G., González-Calle, V., Galotti, M., Gyawali, B., Huntly, B.J.P., Jäger, U., Latino, N.J., Malcovati, L., Oosting, S.F., Ossenkoppele, G., Piccart, M., Raderer, M., Scarfò, L., Trapani, D., Zielinski, C.C., Wester, R., Zygoura, P., Macintyre, E., Cherny, N.I.

“…The European Society for Medical Oncology (ESMO)-Magnitude of Clinical Benefit Scale (MCBS) has been accepted as a robust tool to evaluate the magnitude of…”
Get full text

The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia by Scielzo, C, Apollonio, B, Scarfò, L, Janus, A, Muzio, M, ten Hacken, E, Ghia, P, Caligaris-Cappio, F

“…Malignant B lymphocytes from chronic lymphocytic leukemia (CLL) patients maintain the capacity to respond to CD40 ligation, among other microenvironmental…”
Get full text

IκBε deficiency accelerates disease development in chronic lymphocytic leukemia by Bordini, Jessica, Lenzi, Chiara, Frenquelli, Michela, Morabito, Alessia, Pseftogas, Athanasios, Belloni, Daniela, Mansouri, Larry, Tsiolas, George, Perotta, Eleonora, Ranghetti, Pamela, Gandini, Francesca, Genova, Francesca, Hägerstrand, Daniel, Gavriilidis, Georgios, Keisaris, Sofoklis, Pechlivanis, Nikolaos, Davi, Frederic, Kay, Neil E., Langerak, Anton W., Pospisilova, Sarka, Scarfò, Lydia, Makris, Antonios, Psomopoulos, Fotis E., Stamatopoulos, Kostas, Rosenquist, Richard, Campanella, Alessandro, Ghia, Paolo

“…The NFKBIE gene, which encodes the NF-κB inhibitor IκBε, is mutated in 3–7% of patients with chronic lymphocytic leukemia (CLL). The most recurrent alteration…”
Get full text

The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia by Hägerstrand, Daniel, Oder, Blaž, Cortese, Diego, Qu, Ying, Binzer-Panchal, Amrei, Österholm, Cecilia, Del Peso Santos, Teresa, Rabbani, Leily, Asl, Hassan Foroughi, Skaftason, Aron, Ljungström, Viktor, Lundholm, August, Koutroumani, Maria, Haider, Zahra, Jylhä, Cecilia, Mollstedt, John, Mansouri, Larry, Plevova, Karla, Agathangelidis, Andreas, Scarfò, Lydia, Armand, Marine, Muggen, Alice F., Kay, Neil E., Shanafelt, Tait, Rossi, Davide, Orre, Lukas M., Pospisilova, Sarka, Barylyuk, Konstantin, Davi, Frederic, Vesterlund, Mattias, Langerak, Anton W., Lehtiö, Janne, Ghia, Paolo, Stamatopoulos, Kostas, Sutton, Lesley-Ann, Rosenquist, Richard

“…SF3B1 mutations are recurrent in chronic lymphocytic leukemia (CLL), particularly enriched in clinically aggressive stereotyped subset #2. To investigate their…”
Get full text

EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME by Frustaci, A. M., Montillo, M., Rossi, D., Zinzani, P. L., Motta, M., Gaidano, G., Quaresmini, G., Scarfò, L., Pietrasanta, D., Coscia, M., Deodato, M., Zamprogna, G., Cairoli, R., Stüssi, G., Zucca, E., Pileri, S., Zenz, T., Tedeschi, A.

Get full text

High-throughput analysis of the T cell receptor gene repertoire in low-count monoclonal B cell lymphocytosis reveals a distinct profile from chronic lymphocytic leukemia by Agathangelidis, Andreas, Galigalidou, Chrysi, Scarfò, Lydia, Moysiadis, Theodoros, Rovida, Alessandra, Vlachonikola, Elisavet, Sofou, Electra, Psomopoulos, Fotis, Vardi, Anna, Ranghetti, Pamela, Siorenta, Alexandra, Galanis, Alex, Stamatopoulos, Kostas, Chatzidimitriou, Anastasia, Ghia, Paolo

Get full text

MOLTO, A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON VENETOCLAX, ATEZOLIZUMAB, OBINUTUZUMAB IN RICHTER TRANSFORMATION: SAFETY INTERIM ANALYSIS by Frustaci, A. M., Tedeschi, A., Zinzani, P. L., Pietrasanta, D., Coscia, M., Zenz, T., Motta, M., Gaidano, G., Scarfò, L., Deodato, M., Zamprogna, G., Vitale, C., Cairoli, R., Rossi, D., Montillo, M.

Get full text

P597: HIGH DOSE IRON IMPAIRS MALIGNANT B‐CELL VIABILITY IN CHRONIC LYMPHOCYTIC LEUKEMIA by Bordini, J., Lenzi, C., Toscani, L., Ranghetti, P., Perotta, E., Scarfò, L., Ghia, P., Campanella, A.

Get full text

PB2362: BEST PRACTICES ON EMPOWERING AND INVOLVING PATIENTS LIVING WITH HEMATOLOGICAL MALIGNANCIES ON THE DEVELOPMENT OF NOVEL PATIENT‐REPORTED OUTCOME MEASURES by Vrontaras, N., Kyrou, D., Kapetanakis, A., Tsakona, D., Karamanidou, C., Scarfò, L., Ghia, P., Stamatopoulos, K.

Get full text

Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities by Stamatopoulos, Kostas, Pavlova, Sarka, Al‐Sawaf, Othman, Chatzikonstantinou, Thomas, Karamanidou, Christina, Gaidano, Gianluca, Cymbalista, Florence, Kater, Arnon P., Rawstron, Andy, Scarfò, Lydia, Ghia, Paolo, Rosenquist, Richard

“…Patients with chronic lymphocytic leukemia (CLL) exhibit diverse clinical outcomes. An expanding array of genetic tests is now employed to facilitate the…”
Get full text

EFFICACY AND DISCONTINUATION RATE OF IBRUTINIB IN TREATMENT NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH TP53 ABNORMALITIES. A REAL‐LIFE CAMPUS CLL STUDY by Visentin, A., Mauro, F. R., Cibien, F., Vitale, C., Reda, G., Fresa, A., Ciolli, S., Pietrasanta, D., Marchetti, M., Murru, R., Gentile, M., Rigolin, G. M., Quaglia, F. M., Scarfò, L., Sportoletti, P., Pravato, S., Romano Gargarella, L., Facco, M., Piazza, F., Coscia, M., Laurenti, L., Molica, S., Pizzolo, G., Foà, R., Cuneo, A., Trentim, L.

Get full text

IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA by Condoluci, A., Terzi‐di‐Bergamo, L., Forestieri, G., Moia, R., Deambrogi, C., Deodato, M., Frustaci, A. M., Merli, M., Mattarucchi, R., Autore, F., Fahrni, G., Scarfò, L., Gussetti, D., Bulian, P., Zanatta, A., Spina, V., Faderl, M. R., Bruscaggin, A., Pini, K., Piffaretti, D., Koch, R., Pirosa, M. C., Cittone, M. G., Passweg, J., Cavalli, F., Zucca, E., Gerber, B., Gillessen, S., Stüssi, G., Gattei, V., Ghia, P., Gregor, M., Laurenti, L., Passamonti, F., Tedeschi, A., Gaidano, G., Rossi, D.

Get full text

P593: MULTIDIMENSIONAL ANALYSIS OF THE B CELL RECEPTOR OFFERS INSIGHT INTO THE ONTOGENETIC RELATIONSHIP OF MONOCLONAL B‐CELL LYMPHOCYTOSIS WITH CHRONIC LYMPHOCYTIC LEUKEMIA by Agathangelidis, A., Galigalidou, C., Iatrou, A., Zaragoza‐Infante, L., Scarfò, L., Maniou, M. C., Ranghetti, P., Pechlivanis, N., Junet, V., Skaftason, A., Tsagiopoulou, M., Psomopoulos, F., Rosenquist, R., Ghia, P., Chatzidimitriou, A., Stamatopoulos, K.

Get full text

PB2349: LESSONS LEARNED FROM THE MYPAL DIGITAL HEALTH INTERVENTION: CAPITALIZING ON THE PATIENT REPORTED OUTCOMES (PRO) PARADIGM TOWARDS A PARTICIPATORY HEALTHCARE FOR PATIENTS WITH HEMATOLOGICAL MALIGNANCIES by Karamanidou, C., Scarfò, L., Doubek, M., Garani‐Papadatos, S., Didi, J., Pontikoglou, C., Kazantzaki, E., Ling, J., Pain, C., Papadaki, H., Rosenquist, R., Stavroyianni, N., Payne, S., Ghia, P., Stamatopoulos, K., Natsiavas, P.

Get full text

A MRD‐GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO VENETOCLAX IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (IMPROVE STUDY) by Ghia, P., Scarfò, L., Coscia, M., Sancetta, R., Ferrario, A., Tedeschi, A., Farina, L., Laurenti, L., Orlandi, E., Reda, G., Motta, M., Carlo Stella, C., Massaia, M., Quaresmini, G., Rossini, F., Ladetto, M., Gaidano, G., Rossi, V., Montillo, M.

Get full text

Combining CD23 chimeric antigen receptor immunotherapy and lenalidomide as a novel therapeutic strategy for chronic lymphocytic leukemia by Bertilaccio, M, Tettamanti, S, Attianese, G. Giordano, Galletti, G, Arcangeli, S, Rodriguez, T, Magnani, C, Barbaglio, F, Scarfò, L, Ponzoni, M, Biondi, A, Caligaris-Cappio, F, Ghia, P, Biagi, E

Get full text

Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation by Farina, L., Barretta, F., Scarfò, L., Bruno, B, Patriarca, F., Frustaci, AM, Coscia, M., Salvetti, C., Quaresmini, G., Fanin, R., Onida, F., Magagnoli, M., Zallio, F., Vallisa, D., Reda, G., Ferrario, A, Corradini, P., Montillo, M

“…•The incidence of relapse at 5 years post-transplantation was 38% in the allogeneic stem cell transplantation (alloSCT) group and 83% in the no-alloSCT group…”
Get full text